MediciNova Inc
MNOV1.350USD
-0.080-5.59%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
66.21MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über MediciNova Inc Unternehmen
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Unternehmensinformationen
BörsenkürzelMNOV
Name des UnternehmensMediciNova Inc
IPO-datumDec 01, 2006
CEODr. Yuichi Iwaki, M.D., Ph.D.
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeDec 01
Addresse4275 Executive Square
StadtLA JOLLA
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl92037
Telefon18583731500
Websitehttps://medicinova.com/
BörsenkürzelMNOV
IPO-datumDec 01, 2006
CEODr. Yuichi Iwaki, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Mr. Jason J. Kruger
Mr. Jason J. Kruger
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2024
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Feb 23
Aktualisiert: Sun, Feb 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
BlackRock Institutional Trust Company, N.A.
1.41%
The Vanguard Group, Inc.
1.27%
Other
81.62%
Aktionäre
Aktionäre
Anteil
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
BlackRock Institutional Trust Company, N.A.
1.41%
The Vanguard Group, Inc.
1.27%
Other
81.62%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
14.01%
Investment Advisor/Hedge Fund
3.34%
Individual Investor
2.98%
Venture Capital
2.25%
Research Firm
1.79%
Hedge Fund
0.47%
Bank and Trust
0.02%
Other
75.13%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
68
12.20M
24.87%
-484.88K
2025Q1
73
12.20M
24.88%
-318.34K
2024Q4
74
12.23M
24.94%
+65.83K
2024Q3
73
11.92M
24.31%
+15.81K
2024Q2
76
11.78M
24.02%
-90.59K
2024Q1
75
11.47M
23.39%
-882.87K
2023Q4
77
11.84M
24.14%
-895.64K
2023Q3
90
12.02M
24.50%
-1.28M
2023Q2
106
12.39M
25.26%
-1.32M
2023Q1
131
12.60M
25.68%
-2.90M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
3D Investment Partners Pte. Ltd
5.50M
11.22%
--
--
Apr 21, 2025
EW Healthcare Partners
1.11M
2.25%
--
--
Mar 31, 2025
Iwaki (Yuichi)
1.09M
2.23%
--
--
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
691.21K
1.41%
-1.45K
-0.21%
Mar 31, 2025
The Vanguard Group, Inc.
623.57K
1.27%
+241.00
+0.04%
Mar 31, 2025
Citi Investment Research (US)
591.96K
1.21%
+90.00K
+17.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
527.00K
1.07%
+12.09K
+2.35%
Mar 31, 2025
Matsuda (Kazuko)
323.00K
0.66%
--
--
Apr 21, 2025
Susquehanna International Group, LLP
250.12K
0.51%
-1.26K
-0.50%
Mar 31, 2025
UBS Financial Services, Inc.
222.20K
0.45%
-538.00
-0.24%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Anteil0.01%
Avantis US Small Cap Equity ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
